日本批准使用捐赠者派生iPS细胞治疗帕金森氏病和心脏衰竭的第一批干细胞疗法。 Japan approves first stem-cell therapies for Parkinson’s and heart failure using donor-derived iPS cells.

日本已成为第一个批准干细胞治疗帕金森病和严重心脏病的国家, Japan has become the first country to approve stem-cell treatments for Parkinson’s disease and severe heart failure, using induced pluripotent stem (iPS) cells derived from healthy donors. 疗程、帕金森的安契普里(Amcheprry for Parkinson)和ReHeart(ReHeart)的心脏衰竭治疗得到有条件的、有时间限制的批准, The therapies, Amchepry for Parkinson’s and ReHeart for heart failure, received conditional, time-limited approval based on small trials showing safety and symptom improvement in some patients. 这些治疗由Sumitomo Pharma和Cuorips开发,旨在取代受损的脑细胞和心脏细胞,预计患者将在几个月内得到护理。 Developed by Sumitomo Pharma and Cuorips, the treatments aim to replace damaged brain and heart cells, with patients expected to receive care within months. 这项突破以山中信也的诺贝尔奖研究为基础,标志着在再生医学方面迈出的重要一步。 The breakthrough builds on Nobel Prize-winning research by Shinya Yamanaka and marks a major step in regenerative medicine.